A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol

BACKGROUND: Luteinising hormone-releasing hormone agonists (LHRHa), used as androgen deprivation therapy (ADT) in prostate cancer (PCa) management, reduce serum oestradiol as well as testosterone, causing bone mineral density (BMD) loss. Transdermal oestradiol is a potential alternative to LHRHa. OB...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur Urol
Autori principali: Langley, Ruth E., Kynaston, Howard G., Alhasso, Abdulla A., Duong, Trinh, Paez, Edgar M., Jovic, Gordana, Scrase, Christopher D., Robertson, Andrew, Cafferty, Fay, Welland, Andrew, Carpenter, Robin, Honeyfield, Lesley, Abel, Richard L., Stone, Michael, Parmar, Mahesh K.B., Abel, Paul D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier Science 2016
Soggetti:
Platinum Priority – Prostate Cancer
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4854173/
https://ncbi.nlm.nih.gov/pubmed/26707868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2015.11.030
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi